Middle East & Africa Cardiac Marker Testing Market

Middle East & Africa Cardiac Marker Testing Market Size & Growth (2023 to 2028):

As Per the Report, the Middle East & Africa Cardiac Marker Testing Market Size is anticipated to grow at 5.26% CAGR from 2023 to 2028 and it is estimated that the market is valued at USD 0.23 billion in 2023 and is expected to reach USD 0.30 billion by 2028.

Cardiac markers are biomarkers used to measure and evaluate heart function. They are primarily discussed in reference to myocardial infarction, but other conditions can lead to an elevation in the cardiac marker level. Most of the early markers identified were enzymes, and as an effect of that, the term "cardiac enzymes" is used every now and then. Be that as it may, not all of the markers are presently used are enzymes.

Factor such as an increase in the incidence and occurrences of cardiovascular diseases is among the main factors driving the market growth.  Furthermore, a number of factors such as growing instances of cardiovascular diseases, the rapidly increasing geriatric population, growing to fund from public-private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the cardiac marker testing market. On the other hand, technical problems related to sample collection and storage and issues related to regulatory and reimburse schemes are expected to hinder the growth of the market.

The fragmented healthcare industry and high operating margins in emerging economies make them attractive to investors when compared to developed economies. Manufacturing these devices products in the developing regions tend to decrease the overall cost of manufacturing, thus reducing the cost of the product without altering the quality.

Middle East & Africa Cardiac Marker Testing Market has been segmented and sub-segmented into the following categories 

• By Type: Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP
• By Product: Reagent, Instrument (Chemiluminescence, Immunofluorescence, Immunochromatography, ELISA))
• By Disease: Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure
• By Testing Lab, POC.
• By Country: KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA

Key Market Participants leading the Middle East & Africa Cardiac Marker Testing Market Profiled in the report are Getinge Group, Medtronic plc, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, Siemens AG, Danaher Corporation, Alere Inc., bioMérieux SA, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd, and Guangzhou Wondfo Biotech Co. Ltd.